USA flag logo/image

An Official Website of the United States Government

Company Information:

Company Name:
Praxis Biologics Inc
Address:
30 Corporate Woods
Rochester, NY 14623
Phone:
N/A
URL:
N/A
EIN:
N/A
DUNS:
N/A
Number of Employees:
N/A
Woman-Owned?:
No
Minority-Owned?:
No
HUBZone-Owned?:
No

Commercialization:

Has been acquired/merged with?:
N/A
Has had Spin-off?:
N/A
Has Had IPO?:
N/A
Year of IPO:
N/A
Has Patents?:
N/A
Number of Patents:
N/A
Total Sales to Date $:
$ 0.00
Total Investment to Date $
$ 0.00
POC Title:
N/A
POC Name:
N/A
POC Phone:
N/A
POC Email:
N/A
Narrative:
N/A

Award Totals:

Program/Phase Award Amount ($) Number of Awards
SBIR Phase I $590,012.00 12
SBIR Phase II $1,000,000.00 2

Award List:

AN HAEMOPHILUS OMP AS A VACCINE CANDIDATE

Award Year / Program / Phase:
1987 / SBIR / Phase I
Award Amount:
$50,000.00
Agency:
HHS
Principal Investigator:
Bruce a green phd
Abstract:
Vaccination is the most cost-effective means of preventing haemophilus influenzae type b (hib) disease. newly developed hib polysaccharide-protein conjugate vaccines being tested are effective in children 2 months and older. however, some infants may not be able to respond to polysaccharide… More

A SALMONELLA ORAL VECTOR AS VACCINE CANDIDATE FOR POULTRY

Award Year / Program / Phase:
1987 / SBIR / Phase I
Award Amount:
$50,000.00
Agency:
USDA
Principal Investigator:
Dr robert n brey iii
Abstract:
The immunological control of various diseases of commercial chickens has been essential to the economic viability of theindustry. coccidiosis is a gastrointestinal protozoal disease of chickens which is estimated to result in annual economic losses to the industry of $300 million. because no widely… More

ORAL MALARIA VACCINE DEVELOPMENT IN A PLASMODIUM BERGHEI MODEL

Award Year / Program / Phase:
1987 / SBIR / Phase I
Award Amount:
$50,000.00
Agency:
HHS
Principal Investigator:
Robert N Brey Iii Phd
Abstract:
N/a

RECOMBINANT RSV F GENE PRODUCTS AS VACCINE CANDIDATES

Award Year / Program / Phase:
1988 / SBIR / Phase I
Award Amount:
$50,000.00
Agency:
HHS
Principal Investigator:
Abstract:
Vaccination is the most cost-effective means of preventing respiratory syncytial virus (rsv) disease. a feasible approach to a safe rsv vaccine is to make a subunit of the virus, and the best candidates are the attachment glycoprotein (gp90) and/or the fusion glycoprotein (gp70). the fusion (f)… More

PURA COMPLEMENTATION FOR PLASMID SELECTION & MAINTENANCE

Award Year / Program / Phase:
1988 / SBIR / Phase I
Award Amount:
$50,000.00
Agency:
HHS
Principal Investigator:
Abstract:
Live attenuated salmonella strains are being investigated asvectors for the delivery of foreign antigens to stimulate a protective immune response against various bacterial, viral,and protozoan diseases. these oral vaccines currently underdevelopment rely on expression of foreign antigens from… More

AN ORAL VACCINE AGAINST ENTEROTOXIGENIC E. COLI

Award Year / Program / Phase:
1988 / SBIR / Phase I
Award Amount:
$50,000.00
Agency:
HHS
Principal Investigator:
Abstract:
Diarrhea is a major cause of morbidity and mortality in developing countries, especially in infants and young children. enterotoxigenic e. coli (etec) cause a significant proportion of this disease, as well as episodes of acute diarrhea experienced by travelers to less developedcountries. all etec… More

MUTANT NONTOXIC FORMS OF PERTUSS TOXIN FOR VACCINES

Award Year / Program / Phase:
1988 / SBIR / Phase I
Award Amount:
$50,000.00
Agency:
HHS
Principal Investigator:
Abstract:
Pertussis toxin (pt) is an important immunogen for development of immunity to pertussis, and chemically inactivated pt is a major component of acellular pertussis vaccines being tested in the clinic. a problem of chemical inactivation is preservation of the toxin's immunogenic properties, while… More

SYNTHETIC PEPTIDES AS CARRIERS FOR CONJUGATE VACCINES.

Award Year / Program / Phase:
1988 / SBIR / Phase I
Award Amount:
$50,000.00
Agency:
HHS
Principal Investigator:
Abstract:
The long term objective of this research is to generate bacterial capsular polysaccharide-peptide conjugate vaccinesthat will protect infants, who unlike older children and adults, can not produce antibodies to polysaccharide antigens. conjugate vaccines that are under development in different… More

FUSIONS OF AN HAEMOPHILUS PAL AS VACCINE CANDIDATES.

Award Year / Program / Phase:
1988 / SBIR / Phase I
Award Amount:
$50,000.00
Agency:
HHS
Principal Investigator:
Abstract:
N/a

ORAL MALARIA VACCINE DEVELOPMENT IN A PLASMODIUM BERGHEI MODEL

Award Year / Program / Phase:
1989 / SBIR / Phase II
Award Amount:
$500,000.00
Agency:
HHS
Principal Investigator:
Robert N Brey Iii Phd
Abstract:
Peptide carrier and recombinant dna-produced plasmodium falciparum sporozoite subunit vaccines have been tested in clinical trials. these vaccines have been designed to induce high-titer protective antisporozoite antibodies. clinical trials have indicated that these vaccines are only partly… More

FUSIONS OF AN HAEMOPHILUS PAL AS VACCINE CANDIDATES.

Award Year / Program / Phase:
1989 / SBIR / Phase II
Award Amount:
$500,000.00
Agency:
HHS
Principal Investigator:
Abstract:
Haemophilus influenzae type b (hib) polysaccharide and polysaccharide-protein conjugate vaccines have been proven effective against hib disease. however, capsular antigen isof no value against non-typable h. influenzae (hi) disease. a 16000 dalton outer membrane peptidoglycan associated lipoprotein… More

RECOMBINANT FLAGELLIN VACCINES

Award Year / Program / Phase:
1989 / SBIR / Phase I
Award Amount:
$46,876.00
Agency:
HHS
Principal Investigator:
Abstract:
Praxis biologics, inc., will conduct experiments to assess the potential of using bacterial flagella as carriers of foreign antigenic determinants. recombinant dna techniques will be used to construct and express hybrid flagellin molecules encoding foreign epitopes that can assemble into flagella on… More

SYNTHETIC CLYCO-CONJUGATE VACCINE AGAINST MENINGOCOCCI

Award Year / Program / Phase:
1989 / SBIR / Phase I
Award Amount:
$50,000.00
Agency:
HHS
Principal Investigator:
Abstract:
The objective of phase i is to prepare synthetic glyco-conjugate vaccines against meningococcal diseases caused by neisseria meningococci serogroups a and c. n. meningitidis is a leading cause of bacterial meningitis in infants, young adults, and in enclosed populations such as in military posts,… More

RECOMBINANT ROTAVIRUS PROTEINS FOR SUBUNIT VACCINE

Award Year / Program / Phase:
1989 / SBIR / Phase I
Award Amount:
$43,136.00
Agency:
HHS
Principal Investigator:
Abstract:
The objective of phase i is to produce a rotavirus assembled-subunit vaccine using recombinant dna technology. specifically, baculovirus-expressed rotavirus proteins vp6 and vp7 will be purified and assembled, in vitro, into double-shelled, virus-like particles, with the inner capsid composed of vp6… More